RET and medullary thyroid gland carcinoma: Vandetanib, an oral inhibitor of RET, vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor signalling, has shown long-lasting disease control in patients with advanced hereditary MTC.